Apolipoprotein E and apolipoprotein A-1 knock-out mice readily develop amyloid a protein amyloidosis

Clinical Immunology and Immunopathology

Volumn 85, Issue 1, 1997, Pages 104-108

  Elliott Bryant, Rosemary ^a   Cathcart, Edgar S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FEMALE; HYPERLIPOPROTEINEMIA TYPE 3; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SENILE PLAQUE;

EID: 0031260287     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4397     Document Type: Article

References (35)

1. Cathcart E. S. Amyloidosis. Textbook of Rheumatology. 1993;Saunders, Philadelphia. p. 1413-1428.
2. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and Kuru plaque amyloid in Creutzfeld-Jakob disease. Brain Res. 541:1991;163-166.
3. Wisniewski T., Frangione B. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135:1992;235-238.
4. Wisniewski T., Lalowski M., Golabek A. A., Vogel T., Frangione B. Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet. 345:1995;956-995.
5. Wisniewski T., Golabek A. A., Kida E., Wisniewski K. E., Frangione B. Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am. J. Pathol. 147:1995;238-240.
6. Harr S. D., Uint L., Hollister R., Hyman B. T., Mendez A. J. Brain expression of apolipoproteins E, J, and A-1 in Alzheimer's disease. J. Neurochem. 66:1996;2429-2435.
7. Mahley R. W. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science. 240:1988;622-629.
8. Wetterau J. R., Aggerbeck L. P., Rall S. C. Jr., Weisgraber K. H. Human apolipoprotein E3 in aqueous solution. Evidence for two structural domains. J. Biol. Chem. 263:1988;6240-6248.
9. Weisgraber K. H. Apolipoprotein E distribution among human plasma lipoproteins: role of cysteine arginine interchange at residue 112. J. Lipid Res. 31:1990;1503-1511.
10. Taniguchi Y., Yorioka N., Yamashita K., Oda H., Nie L. F., Yeu X. F., Okushin S., Nishida S., Kushihata S., Yamakido M. Immunohistochemical localization of apolipoprotein E in renal amyloidosis. J. Med. Sci. 45:1996;11-14.
11. Prelli F., Pras M., Shtrasburg S., Frangione B. Characterization of high molecular weight amyloid A proteins. Scand. J. Immunol. 33:1991;783-786.
12. Castano E. M., Prelli F., Pras M., Frangione B. Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L: Implications for amyloidogenesis and Alzheimer's disease. J. Biol. Chem. 270:1995;17610-17615.
13. Soto C., Castano E. M., Prelli F., Kumar R. A., Baumann M. Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's gelsolin and AA amyloids. FEBS Lett. 371:1995;110-114.
14. Gallo G., Wisniewski T., Choi-Miura N-H., Ghiso J., Frangione B. Potential role of apolipoprotein E in fibrillogenesis. Am. J. Pathol. 145:1994;526-530.
15. Banka C. L., Yuan T., de Beer M. C., Kindy M., Curtiss L. K., de Beer F. C. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J. Lipid. Res. 36:1995;1058-1065.
16. Eisenberg S. High density lipoprotein metabolism. J. Lipid. Res. 25:1984;1017-1058.
17. Hoffman J. S., Benditt E. P. Changes in high density lipoprotein content following endotoxin administration in the mouse: Formation of serum amyloid protein-rich subfractions. J. Biol. Chem. 257:1982;10510-10517.
18. Westermark P., Mucchiano G., Marthin T., Johnson K. H., Sletten K. Apolipoprotein A1-derived amyloid in human aortic atherosclerotic plaques. Am. J. Pathol. 147:1995;1186-1192.
19. Cohen A. S., Cathcart E. S. Casein induced experimental amyloidosis. Review of cellular and immunological aspects. Methods Achievements Exp. Pathol. 6:1972;207-242.
20. M. A. Axelrad, R. Kisilevsky, J. Willmer, M. Skinner, A. S. Cohen, Further characterization of amyloid-enhancing factor, Lab. Invest. 47, 139, 146.
21. Kindy M. S., King A. R., Perry G., de Beer M. C., de Beer F. C. Association of apolipoprotein E with murine amyloid A protein amyloid. Lab. Invest. 73:1995;469-475.
22. Peidrahita J. A., Zhang S. H., Hagaman J. R., Oliver P. M., Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA. 89:1992;4471-4475.
23. Williamson R. D., Lee J., Hagaman J. R., Maeda M. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 89:1992;7134-7138.
24. Sipe J. D., Carreras I., Gonnerman W. A., Cathcart E. S., de Beer M. C., de Beer F. C. Characterisation of the inbred CE/J mouse strain as amyloid resistant. Am. J. Pathol. 143:1993;1480-1485.
25. Plump A. S., Smith J. D., Hayek T., Aalto-Setalo K., Walsh A., Verstuft J. G., Rubin E. M., Breslow J. L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E deficient mice created by homologous recombination in ES cells. Cell. 71:1992;343-353.
26. Williams R. C. Jr., Cathcart E. S., Calkins E., Fite G. L., Rubio J. B., Cohen A. S. Secondary amyloidosis in lepromatous leprosy: possible relations of diet and environment. Ann. Int. Med. 62:1965;1000-1007.
27. Cathcart E. S., Leslie A. C., Meydani N. S., Gonnerman W. A., Hayes K. C. A fish oil diet retards experimental amyloidosis, modulates lymphocyte function, and decreases macrophage arachidonate metabolism in mice. J. Immunol. 139:1987;1850-1854.
28. Rajavashist T. B., Kapstein J. S., Reue L. K., Lusis A. J. Evolution of apolipoprotein E: Mouse sequence and evidence for an 11-nucleotide ancestral unit. Proc. Natl. Acad. Sci. USA. 82:1985;8085-8089.
29. Evans K. C., Berger E. P., Cho C. G., Weisgraber K. H., Lansbury P. T. Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 92:1995;763-767.
30. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild I., Salvesen G. S., Roses A. D. High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 90:1993;1977-1981.
31. Corder E. H., Saunders A. M., Strittmatter W. J., Schechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak V. M. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 262:1993;921-923.
32. Hasegawa H., Nish S-I., Ito S., Saeki T., Kuroda T., Kimura H., Watababe T., Nakano M., Gejyo F., Arakawa M. High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. Arthritis. Rheum. 39:1996;1728-1732.
33. Lovat L. B., Booth S. E., Booth D. R., Madhoo S., Holmgren G., Hawkins P. N., Soutar A. K., Pepys M. B. Apolipoprotein E4 genotype is not a risk factor for systemic AA amyloidosis or familial amyloid polyneuropathy. Amyloid. 2:1995;163-166.
34. Kindy M. S., de Beer F. C., Markesbery W. R., Pras M., Aksentijevich I., Kastner D., Kyle R., Solomon A., Woo P. Apolipoprotein E genotypes in AA and AL amyloidoses. Amyloid. 2:1995;159-162.
35. Booth D. R., Si-Yen T., Booth S. E., Tennent G. A., Hutchinson W. L., Hsuan J. J., Totty N. F., Truong O., Soutar A. K., Hawkins P. N., Bruguera M., Caballeria J., Sole M., Campistol J. M., Pepy M. B. Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein A1 gene. J. Clin. Invest. 97:1996;2714-2721.